Skip to Main Content

Paper Details

Clinical and Molecular Prevalence of Lipodystrophy in an Unascertained Large Clinical Care Cohort.
Diabetes
41
2020
Dunnigan familial partial lipodystrophy, LMNA, Lipodystrophies, Lipodystrophy, Partial lipodystrophy, R482Q, diabetes, dyslipidemia, inherited lipodystrophies, lipodystrophy, lipodystrophy disorders, metabolic abnormalities, metabolic disorders, metabolic dysregulation, p.R482Q, patients
Author NameAffiliation
Cristopher V Van HoutRegeneron Pharmaceuticals, Inc.
Joseph B Leader
Michael F Murray
Michael F Murray
Jeffrey G ReidRegeneron Pharmaceuticals, Inc.
Jeffrey G ReidRegeneron Pharmaceuticals, Inc.
David J Carey
David J Carey
John D OvertonRegeneron Pharmaceuticals, Inc.
John D OvertonRegeneron Pharmaceuticals, Inc.
Alan R ShuldinerRegeneron Pharmaceuticals, Inc.
Alan R ShuldinerRegeneron Pharmaceuticals, Inc.
Omri GottesmanRegeneron Pharmaceuticals, Inc.
Omri GottesmanRegeneron Pharmaceuticals, Inc.
Jesper GromadaRegeneron Pharmaceuticals, Inc.
Aris BarasRegeneron Pharmaceuticals, Inc.
  • 1 - 16

Datasets

Release 1.2